Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK American Depositary Shares), an increase in the notional allocation of ADSs occurred on June 8, 2012. The transaction price was $44.62 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: June 8, 2012 (Notification date: June 11, 2012).
- Instrument: GSK American Depositary Shares (ADSs).
- Price: $44.62 per ADS.
- Parties Involved: Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Allocation Details: Dr. M M Slaoui received 0 ADSs; Dr. K Slaoui received 5 ADSs.
- Context: The change resulted from a revaluation of the cash element within the US Retirement Savings Plan.